FilingReader Intelligence
Kissei licenses thyroid eye disease treatments from Viridian
July 30, 2025 at 08:10 AM UTC•By FilingReader AI
Kissei Pharmaceutical has secured exclusive Japanese development and sales rights for Veligrotug and VRDN-003, two thyroid eye disease treatments, through a licensing agreement with Viridian Therapeutics.
Both are monoclonal antibodies targeting IGF-1R to reduce inflammation in orbital tissues. Veligrotug awaits US regulatory submission, while VRDN-003 is in global Phase III trials.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
TSE:4547•Tokyo Stock Exchange
News Alerts
Get instant email alerts when Kissei Pharmaceutical publishes news
Free account required • Unsubscribe anytime